The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
RAGE Control of Diabetic Nephropathy in a Mouse Model
Abstract
Diabetic nephropathy is a major microvascular complication in long-standing diabetic patients who eventually undergo renal dialysis or transplantation. To prevent development of this disease and to improve advanced kidney injury, effective therapies directed toward the key molecular target are required. In this study, we examined whether inhibition of the receptor for advanced glycation end products (RAGE) could attenuate changes in the diabetic kidney. Here, we show that inactivation of the RAGE gene in a mouse model of diabetic nephropathy results in significant suppression of kidney changes, including kidney enlargement, increased glomerular cell number, mesangial expansion, advanced glomerulosclerosis, increased albuminuria, and increased serum creatinine compared with wild-type diabetic mice. The degree of kidney injury was proportional to RAGE gene dosage. Furthermore, we show that low–molecular weight heparin (LMWH) can bind RAGE at a mean equilibrium dissociation constant (Kd) value of ∼17 nmol/l and act as an antagonist to RAGE. LMWH treatment of mice significantly prevented albuminuria and increased glomerular cell number, mesangial expansion, and glomerulosclerosis in a dose-dependent manner; it also significantly improved the indexes of advanced-stage diabetic nephropathy. This study provides insight into the pathological role of RAGE in both early- and advanced-phase diabetic nephropathy and suggests that RAGE antagonists will be a useful remedy in the treatment of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., & Stern, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118175 · Cited by 896 · cited 1×
“sion molecule (VCAM)-1 assay was performed by ELISA as described (28).”
MethodYONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Self-citationTaylor, K. R., & Gallo, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.05-4682rev · Cited by 639
Asano, M., Furukawa, K., Kido, M., Matsumoto, S., Umesaki, Y., Kochibe, N., & Iwakura, Y. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.1850 · Cited by 270
Self-citationLong-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Okuda, M., & Yamamoto, Y. (2004) · Clinical and Laboratory Haematology · doi:10.1111/j.1365-2257.2004.00605.x · Cited by 47
Self-citation
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0786 · Cited by 434
Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407
The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212217 · Cited by 381
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
Dangers Within: DAMP Responses to Damage and Cell Death in Kidney Disease
Rosin, D. L., & Okusa, M. D. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040430 · Cited by 284
Diabetic nephropathy – is this an immune disorder?
Tesch, G. H. (2017) · Clinical Science · doi:10.1042/cs20160636 · Cited by 264
Septic Shock Is Associated with Receptor for Advanced Glycation End Products Ligation of LPS
Yamamoto, Y., Harashima, A., Saito, H., Tsuneyama, K., Munesue, S., Motoyoshi, S., Han, D., Watanabe, T., Asano, M., Takasawa, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002253 · Cited by 207
Self-citationVascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice
Yamamoto, Y., Liang, M., Munesue, S., Deguchi, K., Harashima, A., Furuhara, K., Yuhi, T., Zhong, J., Akther, S., Goto, H., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0325-6 · Cited by 171
Self-citationAdvanced glycation endproducts and its receptor for advanced glycation endproducts in obesity
Gaens, K. H., Stehouwer, C. D., & Schalkwijk, C. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aea13 · Cited by 166
Sourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.029 · Cited by 143
Liu, Y.-W., Zhu, X., Zhang, L., Lu, Q., Wang, J.-Y., Zhang, F., Guo, H., Yin, J.-L., & Yin, X.-X. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.029 · Cited by 72
Ueno, H., Koyama, H., Shoji, T., Monden, M., Fukumoto, S., Tanaka, S., Otsuka, Y., Mima, Y., Morioka, T., Mori, K., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.006 · Cited by 65
Self-citationRAGE mediates vascular injury and inflammation after global cerebral ischemia
Kamide, T., Kitao, Y., Takeichi, T., Okada, A., Mohri, H., Schmidt, A. M., Kawano, T., Munesue, S., Yamamoto, Y., Yamamoto, H., et al. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2011.12.008 · Cited by 60
Self-citationArguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700008 · Cited by 58
Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells
Yamamoto, Y., Yonekura, H., Watanabe, T., Sakurai, S., Li, H., Harashima, A., Myint, K. M., Osawa, M., Takeuchi, A., Takeuchi, M., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.030 · Cited by 44
Self-citationDeletion of RAGE Causes Hyperactivity and Increased Sensitivity to Auditory Stimuli in Mice
Sakatani, S., Yamada, K., Homma, C., Munesue, S., Yamamoto, Y., Yamamoto, H., & Hirase, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008309 · Cited by 42
Self-citationMotoyoshi, S., Yamamoto, Y., Munesue, S., Igawa, H., Harashima, A., Saito, H., Han, D., Watanabe, T., Sato, H., & Yamamoto, H. (2014) · Biochemical Journal · doi:10.1042/bj20140084 · Cited by 20
Self-citationEffects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice
Liu, L., Killoy, K. M., Vargas, M. R., Yamamoto, Y., & Pehar, M. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.636 · Cited by 17
Self-citation
Metadata
- Authors
- Myint, K.-M., Yamamoto, Y., Doi, T., Kato, I., Harashima, A., Yonekura, H., Watanabe, T., Shinohara, H., Takeuchi, M., Tsuneyama, K., Hashimoto, N., Asano, M., Takasawa, S., Okamoto, H., & Yamamoto, H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-09-01
- Volume
- 55
- Issue
- 9
- Pages
- 2510-2522
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2409521209
- Cited by
- 249
- References
- 6
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.